Standard premedication and antiinfective prophylaxis strategies for T-cell engaging therapies at the Myeloma Institute at University of Miami
| Intervention . | Details . |
|---|---|
| Tocilizumab | A single dose of 8 mg/kg (capped at 800 mg) was given 1 hour before the first step-up dose only |
| Acetaminophen | Before initial step-up dosing schedule following USPI recommendations |
| Diphenhydramine | Before initial step-up dosing schedule following USPI recommendations |
| Dexamethasone | Before initial step-up dosing schedule following USPI recommendations |
| Acyclovir (valacyclovir alternative) | Before the first step-up dose and continued throughout treatment |
| Sulfamethoxazole/trimethoprim (atovaquone or pentamidine alternative) | Before the first step-up dose and continued throughout treatment |
| Levofloxacin (cefdinir alternative) | 500 mg once a day before the first step-up dose continued for at least the first 30 days of treatment |
| Fluconazole | Only initiated if neutropenic and continued until recovery. MOLD active agents only added for prolonged neutropenia on a case-by-case basis |
| Entecavir (tenofovir alternative) | 0.5 mg once a day; only initiated if HBsAg or HBcAb positive on screening before first step-up dose |
| IV immunoglobulin | Initiated 0.4 g/kg (ideal body weight) once a month for all patients with serum immunoglobulin G of <400 mg/dL |
| Granulocyte colony-stimulating factor | Only initiated if neutropenic and continued until recovery at the discretion of the treating provider |
| Intervention . | Details . |
|---|---|
| Tocilizumab | A single dose of 8 mg/kg (capped at 800 mg) was given 1 hour before the first step-up dose only |
| Acetaminophen | Before initial step-up dosing schedule following USPI recommendations |
| Diphenhydramine | Before initial step-up dosing schedule following USPI recommendations |
| Dexamethasone | Before initial step-up dosing schedule following USPI recommendations |
| Acyclovir (valacyclovir alternative) | Before the first step-up dose and continued throughout treatment |
| Sulfamethoxazole/trimethoprim (atovaquone or pentamidine alternative) | Before the first step-up dose and continued throughout treatment |
| Levofloxacin (cefdinir alternative) | 500 mg once a day before the first step-up dose continued for at least the first 30 days of treatment |
| Fluconazole | Only initiated if neutropenic and continued until recovery. MOLD active agents only added for prolonged neutropenia on a case-by-case basis |
| Entecavir (tenofovir alternative) | 0.5 mg once a day; only initiated if HBsAg or HBcAb positive on screening before first step-up dose |
| IV immunoglobulin | Initiated 0.4 g/kg (ideal body weight) once a month for all patients with serum immunoglobulin G of <400 mg/dL |
| Granulocyte colony-stimulating factor | Only initiated if neutropenic and continued until recovery at the discretion of the treating provider |
HBcAb, hepatitis B core antibody; HBsAg, hepatitis B surface antigen.